Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes *Advertisement*
Phillip Home Send to Friends Free Subscription Give Comments 中文版
14 Jul, 2017 (Friday)


Kanion Pharmaceutical(600557)
Analysis:
The 2017 NDRL contains the company`s eight drugs chosen for the first time, including five exclusives, such as Large-strain Rhodiola Capsule, Longxue Tongluo Capsule, and Jiuwei Xifeng Granules, and five varieties upgraded from Grade B to Grade A, including three exclusives, Guizhifuling Capsule, Guizhifuling Tablet and Yaobitong Capsule. In total, 110 varieties have entered the NDRL, of which 20 are exclusives. In addition, tightened usage restriction has been imposed on Reduning Injection, and Diterpene Ginkgolides Meglumine Injection anticipates access to NDRL through negotiation. Overall, the company is one of the main beneficiaries of the NDRL revision, through which many of its varieties may grow into premier ones. Kanion Pharmaceutical takes the lead in R&D investment and has a three-dimensional product structure. Plus with the marketing reform of mixed-line sales, the company`s multiple products may become premier varieties supporting its fast growth. Meanwhile, the company`s share price, less than the private placement price of around RMB20 as in the previous Senior Management Incentive Plan, provides margin of safety.
Strategy:
Buy-in Price: CNY16.45, Target Price: CNY18.00, Cut Loss Price: CNY16.00


Kerry Properties (683.HK) - Completion of Key Projects Prompts Repricing Opportunity

Investment Summary

- Several key property development projects will be completed in FY2017, bringing substantial revenue to the company

- Large proportion of stable recurring revenue contributed by the investment property and hotel segments

Business Overview

Better than expected FY2016 result: Kerry Properties achieved sizable growth in FY2016. Revenue grew 25.0% to HK$12,991Mn. Gross profit margin increased from 37.6% in FY2015 to 45.1% in FY2016, leading gross profit in FY2016 to increase 49.7% to HK$5,856Mn. The increase in gross profit is mainly caused by the increase in the gross profit margin of the property development segment. In FY2016, Kerry Properties achieved very strong sales. Contracted sales in Hong Kong rose from HK$5.8Bn in FY2015 to HK$12.2Bn in FY2016. Contracted sales in China rose from HK$6.8Bn in FY2015 to HK$14.2Bn in FY2016. Net profit attributable to the shareholders increased 18.2% to HK$6,537Mn. In FY2016, Earnings per Share increased 18% to HK$4.53 and the company declared a final dividend of HK$0.80, 33% higher than last year.

Several major properties will be completed in FY2017: Several major property development projects in both Hong Kong and China will be completed in FY2017. In particular, the HK$12.2Bn contracted sales of Hong Kong segment in FY2016 were primarily the result of the sales of the two key properties in Hong Kong, namely Martin Heights and The Bloomsway. For the HK$14.2Bn contracted sales of China segment, it was mainly contributed by Nanjing Jinling Arcadia Court, Hangzhou Zhijiang Castalia Court and Chengdu Metropolis-Arcadia Court etc. A substantial portion of the contracted sales is expected to be recognised in FY2017 because some projects are expected to be completed in FY2017. The key Hong Kong projects expected to be completed in FY2017 are as follow:

The key projects in China to be completed in FY2017 are as follow:

For the remaining unsold units, particularly those in Hong Kong, Kerry Properties plans to sell the remaining units after the whole projects are completed. In fact, using the data of recent transaction, we expect the remaining units of Martin Heights and The Bloomsway to worth about HK$16Bn, having the potential to add sizable revenue to the company.

Besides, the company has a strong development pipeline and the projects and land reserve are enough for the company's development for the next 4 years. There are several property development projects set to be completed in FY2018 and FY2019. They are located in Beacon Hills, Sai Ying Poon and Ho Man Tin, all of which are expected to aim at high end home seekers and investors and are expected to have strong demand and sales.

Investment properties segment is growing steadily: The investment property segment is expected to have a considerable growth, caused by the completion of a new property originally planned for sales, Shan Kwong Road project. The project has a GFA of 81,217 square foot and provides 106 units. Rent per square foot is expected to be HK$50-HK$70 per month and the annual rental income, assuming a 100% occupancy rate, from the property is expected to be approximately HK$60Mn. The project is expected to be completed in FY2017.

Besides, Kerry Properties also has several large investment properties construction projects ongoing in China, such as the Shenzhen Qianhai projects and Hangzhou Kerry Centre, with completion date ranging from FY2017 to FY2020. The type of properties ranges from residential and office to retail and hotel. Key investment properties under development are as follow:

Investment Thesis, Valuation and Risk

Our valuation model suggests a target price of HK$33.60: Kerry Properties has achieved strong sales in its Hong Kong projects, namely The Bloomsway and Martin Heights, and at the same time has a large and stable stream of recurring revenue from the investment property segment. Moreover, it still has large number of unsold units with high market value in the Martin Heights and The Bloomsway projects, potentially adding large stream of revenue to the company. Therefore, a target price of HK$33.60, corresponding to a P/E and P/B of 6.08x and 0.40x respecitvely, has been assigned, with a `Buy` rating assigned. (Closing price as at 12 Jul 2017)

Financials

Click Here for PDF format...




Recommendation on 14-7-2017
RecommendationBuy
Price on Recommendation Date$ 26.400
Suggested purchase priceN/A
Target Price$ 33.600
Writer Info
John Wong
(Research Analyst)
Tel: +852 2277 6527
Email:
johnycwong@phillip.com.hk

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Phillip Research - Hong Kong 輝立研究部 – 香港及中國
Company Stock Code Last Update Suggestion Target Price Price on Recom
Information Techology Research Department N/A+852 2277 6527research@phillip.com.hk
Goldpac Group331527/03/2017Buy32.4
O-Net Technologies87727/09/2016No Rating4.02
Transportation and Automobiles Zhang Jing (86) 2151699200-103zhangjing@phillip.com.cn
Harmony Auto383612/07/2017Accumulate4.13.78
GBIA60000405/07/2017Accumulate22.1819.29
Insurance Research Department (86) 21 51699400-110research@phillip.com.cn
Media & Publishing Research Department (+ 86 21 51699400-107)research@phillip.com.cn
Wisdom Sports Group166111/07/2016Buy3.32.18
NetDragon77716/06/2016Buy28.422.9
Pharmaceutical Fan Guohe  (+ 86 21 51699400-110)fanguohe@phillip.com.cn
Haohai Biological Technology682611/07/2017Buy51.241.6
Haohai Biological Technology682610/07/2017Buy51.241.6
Industrial Goods Ocean Pan +852 2277 6515oceanpan@phillip.com.hk
TK Group228320/03/2017Accumulate2.82.38
TK Group228310/01/2017Buy2.82.18
Health & Personal Care Fan Guohe  (+ 86 21 51699400-110)fanguohe@phillip.com.cn
HEC Pharm155802/06/2017Buy22.2417.08
Luye Pharma218622/03/2017Buy6.34.95
New Energy Wang Yannan 86 21 51699400-107wangyannan@phillip.com.cn
HN RENEWABLES95827/02/2017Buy3.52.72
CONCORD NE18224/10/2016Buy0.60.39
Food, Beverage and Retail Research Department (86) 21 51699400-110research@phillip.com.cn
L`OCCITANE97322/05/2017Accumulate1715.3
L`OCCITANE97319/05/2017Accumulate1715.3
Textiles & Clothing Ocean Pan +852 2277 6515oceanpan@phillip.com.hk
JNBY330613/04/2017Accumulate6.65.95
CECEP COSTIN New Materials Group222818/10/2013Buy5.64.23
Telecommunications Fan Guohe + (86) 21 51699400-110fanguohe@phillip.com.cn
Chinasoft International Ltd35410/04/2017Buy5.84.61
Chinasoft International35426/10/2016Buy4.863.72
Mainland Property John Wong +852 2277 6527johnycwong@phillip.com.hk
China Overseas Land & Inv68822/06/2017Accumulate25.122.85
Shenzhen Investment60431/05/2017Accumulate4.13.61
Basic Materials Ocean Pan +852 2277 6515oceanpan@phillip.com.hk
Yip's Chemical40815/06/2017No Rating3.29
ND Paper268905/04/2017Accumulate9.58.35
Utilities Research Department +852 2277 6527research@phillip.com.hk
Beijing Enterprises Water Group Limited (BEWG)37113/07/2017Buy7.686.07
Longma Environmental60368606/07/2017Accumulate41.234.36
Properties John Wong +852 2277 6527johnycwong@phillip.com.hk
Kerry Properties68314/07/2017Buy33.600.000
Far East Consortium3529/06/2017Buy5.34.33
Software & Service Research Department (86) 21 51699400-110research@phillip.com.cn
IGG800221/11/2014Accumulate3.953.44
HC INTERNATIONAL228006/11/2014Buy14.928.8
Hotels and Entertainment John Wong (+ 852 2277 6527)johnycwong@phillip.com.hk
Jinjiang Hotels200608/07/2016Accumulate2.982.49
CUTC60035808/03/2016N/A10.41

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

版權所有, 翻印必究。

Copyright(C) 2017 Phillip Securities (HK) Ltd. All Rights Reserved.